33836153Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, CalabrĂ² L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HLThe Lancet. Respiratory medicineAntibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; MesotheliomaAdult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Male; Middle Aged; Treatment OutcomeEfficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621.Lancet Respir Med2021-04-06T00:00:002021Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461294Aged, 80 and overD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD008654Disorders573090.774622MesotheliomaD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD005260Physiology1992444050.191167FemaleD015331Concepts & IdeasProcedures72727590.604842Cohort StudiesD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleMedicine-Hematology and OncologyAuthorship 145557140.2034010.2034011authors10.2512has subject areaD016896Concepts & Ideas101179490.402389Treatment OutcomeD061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedD000074322851850.820832Antineoplastic Agents, ImmunologicalUniversity of ChicagoHedyKindler32lgBaUZHP75hHlsaUXv9Gq0+s+oHedy Kindler41.78927490000000-87.601250000000002499Kindler, HedyProfessortrue1ProfessorProfessor